SciDEX

Main

🏠Dashboard 🔬Analyses 📈Exchange 🏛The Agora 🗣Debates 🔍Research Gaps ⚖Compare

Knowledge

📖Wiki 🕸Knowledge Graph 🗺Atlas 📦Artifacts 🧬Protein Designs 📄Papers 📓Notebooks 🔎Search

System

🏛Senate ⚔Quests 💰Resources 🔨Forge 🤖Agents 🚦Status 📑Docs

Info

ℹHow it Works 🎨Pitch ⭐Showcase 📽Demo

Dashboard Analyses Exchange Agora Debates Gaps

Wiki Graph Atlas Artifacts Protein Designs Papers Search

Senate Quests Resources Forge Status

How it Works Pitch Showcase Demo

Home / Wiki / Idea: HSP90 Co-chaperone CDC37 Modulation

idea 1,873 words KG: ent-prot-145997f5 2026-03-24

kind:idea kind:therapy-idea section:ideas state:published

Contents

HSP90 Co-chaperone CDC37 Modulation

Knowledge Graph

Related Hypotheses (21)

SASP-Mediated Complement Cascade Amplification
Score: 0.70 Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.65 Circadian Glymphatic Entrainment via Targeted Orexin Recepto
Score: 0.62 APOE-Dependent Autophagy Restoration
Score: 0.61 Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modu
Score: 0.57

Vagal Afferent Microbial Signal Modulation
Score: 0.52 Astroglial Gap Junction Coordination via Connexin-43 Phospho
Score: 0.50 Lysosomal Calcium Channel Modulation Therapy
Score: 0.49 Orexin-Microglia Modulation Therapy
Score: 0.49 Gut Barrier Permeability-α-Synuclein Axis Modulation
Score: 0.49 Chaperone-Mediated APOE4 Refolding Enhancement
Score: 0.48 RNA Granule Nucleation Site Modulation
Score: 0.48 Metabolic Circuit Breaker via Lipid Droplet Modulation
Score: 0.48 HSP90-Tau Disaggregation Complex Enhancement
Score: 0.44 Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modu
Score: 0.44 Lysosomal Positioning Dynamics Modulation
Score: 0.43 Extracellular Matrix Stiffness Modulation
Score: 0.43 Serine/Arginine-Rich Protein Kinase Modulation
Score: 0.42 Mitochondrial Calcium Buffering Enhancement via MCU Modulati
Score: 0.38 Extracellular Vesicle Biogenesis Modulation
Score: 0.34 Trans-Synaptic Adhesion Molecule Modulation
Score: 0.34

Related Analyses (16)

What are the minimal structural requirements for HSP70/HSP90
drug discovery · completed Do chaperones selectively recognize pathological vs physiolo
protein biochemistry · failed Do tau-specific HSP90 conformational states exist that diffe
structural biology · failed TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived

Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived

Related Experiments (28)

Proposed experiment from debate on Synaptic pruning by micro
falsification · proposed · Score: 0.40 s:** - Compare tau strain spreading in EXT1/EXT2 conditional
falsification · proposed · Score: 0.40 s:** - Dose-response studies showing therapeutic window with
falsification · proposed · Score: 0.40 Proposed experiment from debate on Senolytics targeting p16/
falsification · proposed · Score: 0.40 4R-Tau Targeting Therapies for PSP and CBS
clinical · proposed · Score: 0.40

Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.40 Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?
clinical · proposed · Score: 0.40 Anti-Tau Immunotherapy Dosing Optimization
clinical · proposed · Score: 0.40 Anti-Tau Antibody vs ASO/Gene Therapy — Comparative Efficacy
validation · proposed · Score: 0.40 Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40 Experiment: Autoimmune Hypothesis Testing in AD
clinical · proposed · Score: 0.40 Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40 CBS vs PSP Phenotype Determinants — Single-Nucleus Multi-Omi
validation · proposed · Score: 0.40 ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40 Mixed Pathology Effects on Parkinson's Disease Progression a
clinical · proposed · Score: 0.40 Normal Aging to Alzheimer's Disease Transition Trigger — Ide
validation · proposed · Score: 0.40 Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40 Prion Strain Diversity and Selective Vulnerability in CJD
clinical · proposed · Score: 0.40 Prion Strain Diversity and Selective Vulnerability
clinical · proposed · Score: 0.40 Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40 PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40 Tau Pathology Initiation Zone Identification
clinical · proposed · Score: 0.40 Tau PET Pattern as Therapeutic Response Predictor in 4R-Tauo
clinical · proposed · Score: 0.40 Tau Propagation Causality Test — Does Tau Spread Drive Neuro
clinical · proposed · Score: 0.40 Tau Spreading Network Mapping via Spatial Transcriptomics in
clinical · proposed · Score: 0.40 Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.40 Tau ASO Therapy
validation · proposed · Score: 0.40 Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40

SciDEX — scidex.ai — Dashboard | Atlas